PURPOSE: We studied the effectiveness of prophylactic oral ciprofloxacin and rifampin on fever prevention in patients undergoing autologous bone marrow transplantation (ABMT) for breast cancer. Furthermore, we evaluated the toxicity and efficacy of empiric once-daily vancomycin and tobramycin for febrile neutropenia. PATIENTS AND METHODS: Ninety-nine assessable women received prophylactic ciprofloxacin and rifampin after high-dose chemotherapy (HDC) for advanced or high-risk primary breast cancer supported with either bone marrow and peripheral-blood progenitor cells (PBPCs) or bone marrow purged with chemotherapy and monoclonal antibodies. Neutropenic fever was treated with empiric once-daily vancomycin and tobramycin. Patients were compared with historic controls treated with the identical HDC and bone marrow support regimen. RESULTS: In patients treated with bone marrow and PBPCs, the incidence of fever during neutropenia was reduced by ciprofloxacin and rifampin from 98% to 57%. Documented infections were reduced from 42% to 13% (P < .01) and bacteremia from 18% to 0% (P < .001). In purged bone marrow recipients, the overall infection rate decreased from 74% to 17% (P < .001), and bacteremia from 29% to 7%. (P = .02). No patient developed breakthrough bacteremia or sepsis syndrome while on study. Serum creatinine level greater than 1.8 g/dL was noted in 7% of controls and 10% of study patients. Increased ototoxicity was not encountered with the higher peak concentrations of vancomycin and tobramycin. CONCLUSION: The therapeutic strategy of ciprofloxacin and rifampin followed by once-daily vancomycin and tobramycin markedly reduced the incidence of infection and virtually eliminated bacteremia in both purged and nonpurged bone marrow recipients. Once-daily vancomycin and tobramycin was safe and effective and, because of the ease of use, facilitates outpatient management of ABMT patients.
PURPOSE: We studied the effectiveness of prophylactic oral ciprofloxacin and rifampin on fever prevention in patients undergoing autologous bone marrow transplantation (ABMT) for breast cancer. Furthermore, we evaluated the toxicity and efficacy of empiric once-daily vancomycin and tobramycin for febrile neutropenia. PATIENTS AND METHODS: Ninety-nine assessable women received prophylactic ciprofloxacin and rifampin after high-dose chemotherapy (HDC) for advanced or high-risk primary breast cancer supported with either bone marrow and peripheral-blood progenitor cells (PBPCs) or bone marrow purged with chemotherapy and monoclonal antibodies. Neutropenic fever was treated with empiric once-daily vancomycin and tobramycin. Patients were compared with historic controls treated with the identical HDC and bone marrow support regimen. RESULTS: In patients treated with bone marrow and PBPCs, the incidence of fever during neutropenia was reduced by ciprofloxacin and rifampin from 98% to 57%. Documented infections were reduced from 42% to 13% (P < .01) and bacteremia from 18% to 0% (P < .001). In purged bone marrow recipients, the overall infection rate decreased from 74% to 17% (P < .001), and bacteremia from 29% to 7%. (P = .02). No patient developed breakthrough bacteremia or sepsis syndrome while on study. Serum creatinine level greater than 1.8 g/dL was noted in 7% of controls and 10% of study patients. Increased ototoxicity was not encountered with the higher peak concentrations of vancomycin and tobramycin. CONCLUSION: The therapeutic strategy of ciprofloxacin and rifampin followed by once-daily vancomycin and tobramycin markedly reduced the incidence of infection and virtually eliminated bacteremia in both purged and nonpurged bone marrow recipients. Once-daily vancomycin and tobramycin was safe and effective and, because of the ease of use, facilitates outpatient management of ABMT patients.
Authors: W V Kern; K Klose; A S Jellen-Ritter; M Oethinger; J Bohnert; P Kern; S Reuter; H von Baum; R Marre Journal: Eur J Clin Microbiol Infect Dis Date: 2005-02 Impact factor: 3.267
Authors: M Hidalgo; J Hornedo; C Lumbreras; J M Trigo; C Gómez; S Perea; A Ruiz; R Hitt; H Cortés-Funes Journal: Antimicrob Agents Chemother Date: 1997-05 Impact factor: 5.191
Authors: B S Sohn; D H Yoon; S Kim; K Lee; E H Kang; J S Park; D H Lee; S H Kim; J Huh; C Suh Journal: Eur J Clin Microbiol Infect Dis Date: 2011-12-04 Impact factor: 3.267
Authors: Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici Journal: Cochrane Database Syst Rev Date: 2012-01-18
Authors: A Jimeno; A Arcediano; S Bazares; M L Amador; L González-Cortijo; E Ciruelos; L Robles; D Castellano; L Paz-Ares; C Lumbreras; J Hornedo; H Cortés-Funes Journal: Clin Transl Oncol Date: 2006-12 Impact factor: 3.405
Authors: Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston Journal: Support Care Cancer Date: 2004-09 Impact factor: 3.603